@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAhHwJ4IkbdGXbJX7qhiesvjKMxPMYhgN38S-730TmTaI> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAhHwJ4IkbdGXbJX7qhiesvjKMxPMYhgN38S-730TmTaI#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix sdis: <http://resource.belframework.org/belframework/20131211/namespace/selventa-legacy-diseases/> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   sub:_1 hasAgent: sub:_2 ;
    a go:0016301 .
  sub:_2 geneProductOf: hgnc:8032 ;
    a Protein: .
  sub:_3 occursIn: species:9606 ;
    rdf:object sdis:metastasis ;
    rdf:predicate belv:increases ;
    rdf:subject sub:_1 ;
    a rdf:Statement .
  sub:assertion rdfs:label "kin(p(HGNC:NTRK2)) -> path(SDIS:metastasis)" .
}
sub:provenance {
   beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_5 ;
    pav:version "20131211" .
  sub:_4 prov:value "Several anticancer therapies target, albeit indirectly, the PI3K/ Akt1 axis and cause inhibition of Akt1 phosphorylation and induction of apoptosis. Examples include herceptin, which inhibits ErbB2 in breast cancer cells; cyclooxygenase-2 (COX-2) inhibitors, which inhibit COX-2 and PDK1 in colon and prostate cancer; gefitnib (Iressa), which targets mutant epidermal growth factor receptor in lung cancer cells; and imatinib mesylate (Gleevec, STI- 571), which targets bcr-abl in leukemia. Conversely, inhibition of anoikis, which contributes to metastasis by trkB or TWIST, involves Akt activation. Given that Akt1 binds to Par-4 in diverse cell types, the action of these therapeutic agents may involve regulation of Par-4 function via Akt1." ;
    prov:wasQuotedFrom pubmed:16540633 .
  sub:_5 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:16540633 ;
    prov:wasDerivedFrom beldoc: , sub:_4 .
}
sub:pubinfo {
   this: dct:created "2014-07-03T14:32:57.159+02:00"^^xsd:dateTime ;
    pav:createdBy orcid:0000-0001-6818-334X , orcid:0000-0002-1267-0234 .
}